Management of Photodermatosis with Raised Cheek Lesion
For a 44-year-old woman with a raised, non-pruritic cheek lesion worsening after sun exposure, the most appropriate initial treatment is topical corticosteroids (potent formulations like clobetasol propionate) applied to the lesion, with consideration for systemic corticosteroid cover if phototherapy is planned.
Clinical Context and Diagnosis
The presentation—raised lesion on the cheek worsening with sun exposure in a middle-aged woman—suggests a photodermatosis, most likely polymorphic light eruption (PLE) or chronic actinic dermatitis (CAD). The non-pruritic nature and facial location are important distinguishing features.
First-Line Medication Approach
Topical Corticosteroids
- Potent topical steroids (e.g., clobetasol propionate, betamethasone) applied directly to the lesion 1
- Apply immediately after any UV exposure if phototherapy is being considered
- For facial application: 1% hydrocortisone may be preferred to minimize skin atrophy risk 1
Systemic Corticosteroids (If Severe or Refractory)
Oral prednisolone: 40-50 mg daily for the first 2 weeks if initiating phototherapy 1
- This prevents provocation of the photodermatosis during treatment
- Taper over 4 weeks while continuing other therapies 1
For acute flares without phototherapy:
- Short-term prednisolone: 15-30 mg daily for 3-5 days 2
Important Clinical Pitfalls
Critical warning: If this patient proceeds to phototherapy (PUVA or UVB), there is a 12-50% risk of provoking the eruption during the first few exposures 1. This is why corticosteroid prophylaxis is essential.
Chronic Actinic Dermatitis Considerations
If CAD is suspected (more persistent, severe photosensitivity):
- PUVA phototherapy must be undertaken under close supervision with mandatory topical or systemic corticosteroid cover 1
- Consider inpatient supervision for initial treatments 1
- Apply topical betamethasone or hydrocortisone butyrate to trunk and 1% hydrocortisone to face after each of the first six exposures 1
Phototherapy Dosing (If Indicated After Initial Management)
PUVA Regimen for PLE
- 8-MOP (methoxypsoralen) PUVA: twice weekly (current UK standard) 1
- Duration: 12-20 treatments total
- Timing is critical: Administer in early spring to maintain photoprotection through summer 1
Managing Provocation Episodes
If the lesion worsens during treatment:
- Apply potent topical steroid immediately
- Lower dose increments for subsequent treatments
- Omit 1-2 treatments if provocation is severe 1
Alternative Considerations
If Pruritus Develops
18-33% of patients develop pruritus during phototherapy 1
- Manage with oral corticosteroids (dose not specified in guidelines, but typically prednisolone 20-40 mg daily)
Post-Treatment Maintenance
- Continue cautious natural sunlight exposure (2 hours weekly minimum) to maintain photoprotection 1
- Use sunscreens for extended outdoor stays
- Annual desensitization is NOT recommended due to cumulative skin cancer risk 1
Key Contraindications and Cautions
- Long-term PUVA carries significant skin carcinogenicity risk—balance therapeutic benefit against this risk 1
- Avoid conception during PUVA therapy; discontinue if pregnancy occurs 1
- For facial lesions specifically, use lower-potency corticosteroids (1% hydrocortisone) to prevent skin atrophy 1
Practical Algorithm
- Initial management: Potent topical corticosteroid to lesion
- If inadequate response: Add oral prednisolone 40-50 mg daily
- If phototherapy planned: Continue prednisolone cover for first 2 weeks, apply topical steroid after each UV exposure
- Monitor closely: Reduce phototherapy dose if provocation occurs
- Maintenance: Gradual sun exposure post-treatment, avoid annual repeated courses
This approach prioritizes immediate symptom control while preparing for definitive phototherapy if needed, with appropriate safeguards against disease provocation 1.